UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, UCB generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Any health, pharmaceutical and/or life sciences policy stemming from the European institutions, especially in relation to EU Pharmaceutical, Industrial, IP, Research, Digital and Trade strategies.

This includes initiatives related to Antimicrobial resistance (AMR), ATMP Regulation, Brexit, Clinical Trials, Data Protection, AI and Data Strategies, EU industrial policy, EU IP policy incl. SPCs, EU Relative Efficacy Assessment, EU research policy, EU trade policy, Healthcare Systems, HTA & Market Access, EU research programs such as IMI and Horizon Europe, Medical Devices, Orphan Medicinal Products and Paediatric Regulations, Patient access to innovation, Patient safety, Pharmaceuticals in the environment, Sustainability & Sustainable Development Goals.

2

0.75

No lobbyists with EP accreditations

1 FTE (50%)
1 FTE (25%)

People with less than 10% of their time spent on activities covered by the Register are not reported

Data not provided by Register Secretariat due to GDPR

Data not provided by Register Secretariat due to GDPR

II - In-house lobbyists and trade/business/professional associations

Companies & groups